Cargando…
Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease
Background: Reduced glutathione (GSH) is an endogenously synthesized tripeptide depleted early in the course of Parkinson’s disease (PD) and GSH augmentation has been proposed as a therapeutic strategy in PD. Objective: This Phase IIb study was designed to evaluate whether a Phase III study of intra...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
IOS Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438472/ https://www.ncbi.nlm.nih.gov/pubmed/28436395 http://dx.doi.org/10.3233/JPD-161040 |